x |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
o |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
Delaware
|
77-0632186
|
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
|
310
N. Indian Hill Blvd.,
#702
Claremont, California
|
91711
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
415
West Foothill Blvd, Suite 206
Claremont,
California 91711-2766
|
||
(Former
address)
|
Large
accelerated filer o
|
Accelerated
filer o
|
|
Non-accelerated
filer o
|
Smaller
reporting company x
|
Class
|
Outstanding
at November 12, 2008
|
|
Common
Stock, $0.001 par value per share
|
105,063,107
shares
|
PART
I.
|
FINANCIAL
INFORMATION
|
2
|
ITEM
1.
|
FINANCIAL
STATEMENTS
|
2
|
ITEM
2.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
|
18
|
ITEM
3.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
27
|
ITEM
4.
|
CONTROLS
AND PROCEDURES
|
27
|
PART
II.
|
OTHER
INFORMATION
|
28
|
ITEM
1.
|
LEGAL
PROCEEDINGS
|
28
|
ITEM
2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
28
|
ITEM
3.
|
DEFAULTS
UPON SENIOR SECURITIES
|
28
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
28
|
ITEM
5.
|
OTHER
INFORMATION.
|
28
|
ITEM
6.
|
EXHIBITS.
|
28
|
SIGNATURES
|
|
29
|
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
Item
|
September
30, 2008
|
|
December
31, 2007
|
||||
(UNAUDITED)
|
(AUDITED)
|
||||||
ASSETS
|
|||||||
Current
assets
|
|||||||
Cash
and cash equivalents
|
$
|
43,161
|
$
|
61,073
|
|||
Accounts
receivable, net of allowance for doubtful
accounts
of $339,365 and $277,140, respectively
|
747,754
|
470,298
|
|||||
Inventories
|
645,281
|
818,329
|
|||||
Prepaid
expenses
|
17,959
|
70,460
|
|||||
Other
current assets
|
133,235
|
67,372
|
|||||
Total
current assets
|
1,587,390
|
1,487,532
|
|||||
Property,
Plant and Equipment
|
|||||||
Buildings
|
1,244,940
|
1,162,060
|
|||||
Machinery
and equipment
|
707,367
|
660,273
|
|||||
Automobiles
|
81,586
|
76,154
|
|||||
Office
equipment
|
109,025
|
93,231
|
|||||
Computer
software
|
10,582
|
9,877
|
|||||
Property,
plant and equipment - total
|
2,153,500
|
2,001,595
|
|||||
Less:
accumulated depreciation
|
(562,056
|
)
|
(433,690
|
)
|
|||
Property,
plant and equipment - net
|
1,591,444
|
1,567,905
|
|||||
Construction
in progress
|
72,059
|
67,262
|
|||||
Intangible
asset - net
|
265,918
|
296,245
|
|||||
Deferred
financing costs
|
68,293
|
129,793
|
|||||
Deposit
to purchase proprietary technology
|
126,443
|
126,443
|
|||||
Total
assets
|
$
|
3,711,547
|
$
|
3,675,180
|
|||
LIABILITIES
AND SHAREHOLDERS’ EQUITY (DEFICIENCY)
|
|||||||
Current
liabilities
|
|||||||
Accounts
payable
|
$
|
2,052,608
|
$
|
1,635,490
|
|||
Advances
from customers
|
286,444
|
169,553
|
|||||
Construction
costs payable
|
299,904
|
316,902
|
|||||
Due
to related parties - trade
|
271,328
|
177,970
|
|||||
Due
to related parties - non-trade
|
557,497
|
551,654
|
|||||
Current
portion of long-term liabilities
|
1,072,489
|
2,889
|
|||||
Total
current liabilities
|
4,540,270
|
2,854,458
|
|||||
Long-term
liabilities, less current portion
|
|||||||
Unsecured
loans payable
|
1,686,637
|
1,574,350
|
|||||
Bank
notes payable
|
12,904
|
17,988
|
|||||
Long-term
convertible notes payable
|
798,303
|
2,058,625
|
|||||
Less:
discount relating to long-term
convertible
notes payable
|
(504,180
|
)
|
(856,308
|
)
|
|||
Long-term
convertible notes payable - net
|
294,123
|
1,202,317
|
|||||
Total
long-term liabilities
|
1,993,664
|
2,794,655
|
|||||
Minority
interest in a subsidiary
|
85,931
|
110,838
|
|||||
Shareholders’
equity (deficiency)
|
|||||||
Common
stock - $0.001 par value
Authorized
200,000,000 shares. Issued and
outstanding
95,331,706 and 81,519,676 shares at
September
30, 2008 and December 31, 2007
|
95,332
|
81,520
|
|||||
Preferred
stock - $0.001 par value
Authorized
20,000,000 shares, none issued
|
-
|
-
|
|||||
Additional
paid-in capital
|
10,182,144
|
9,217,876
|
|||||
Stock-based
compensation reserve
|
(183,619
|
)
|
(307,053
|
)
|
|||
Deficit
accumulated
|
(12,959,508
|
)
|
(11,074,522
|
)
|
|||
Accumulated
other comprehensive income
|
(42,667
|
)
|
(2,592
|
)
|
|||
Total
shareholders’ equity (deficiency)
|
(2,908,318
|
)
|
(2,084,771
|
)
|
|||
Total
liabilities and stockholders’ equity
|
$
|
3,711,547
|
$
|
3,675,180
|
|||
SEE
ACCOMPANYING NOTES
|
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME
|
(UNAUDITED)
|
Item
|
Three
Months Ended September 30,
|
Nine
Months Ended September 30,
|
|||||||||||
2008
|
|
2007
|
2008
|
2007
|
|||||||||
Net
sales
|
$
|
2,327,315
|
$
|
2,957,972
|
$
|
7,539,083
|
$
|
6,214,712
|
|||||
Cost
of sales
|
2,271,772
|
2,718,712
|
7,353,634
|
5,763,387
|
|||||||||
Gross
profit
|
55,543
|
239,260
|
185,449
|
451,325
|
|||||||||
|
|||||||||||||
Operating
expenses
|
|||||||||||||
Consulting
and professional fees
|
54,980
|
161,241
|
243,757
|
618,380
|
|||||||||
Officers’
compensation
|
59,690
|
58,811
|
178,153
|
213,280
|
|||||||||
General
and administrative
|
211,493
|
275,532
|
686,010
|
651,055
|
|||||||||
Selling
expenses
|
41,051
|
77,650
|
155,632
|
284,916
|
|||||||||
Research
and development
|
42,922
|
41,931
|
144,054
|
134,730
|
|||||||||
Depreciation
and amortization
|
33,930
|
35,234
|
86,748
|
96,098
|
|||||||||
Allowance
and provision
|
42,367
|
(60
|
)
|
42,309
|
604
|
||||||||
Total
operating expenses
|
486,433
|
650,339
|
1,536,663
|
1,999,063
|
|||||||||
Operating
loss
|
(430,890
|
)
|
(411,079
|
)
|
(1,351,214
|
)
|
(1,547,738
|
)
|
|||||
|
|||||||||||||
Interest
expenses
|
(142,868
|
)
|
(171,743
|
)
|
(565,728
|
)
|
(573,647
|
)
|
|||||
Loss
before minority interest in a subsidiary’s
deficit
|
(573,758
|
)
|
(582,822
|
)
|
(1,916,942
|
)
|
(2,121,385
|
)
|
|||||
Minority
interest in a subsidiary’s deficit (profit)
|
5,988
|
(15,699
|
)
|
31,956
|
(8,778
|
)
|
|||||||
Loss
from continuing operations
|
(567,770
|
)
|
(598,521
|
)
|
(1,884,986
|
)
|
(2,130,163
|
)
|
|||||
|
|||||||||||||
Loss
on discontinued operations:
|
|||||||||||||
Discountinued
urea entrepot trade -
Commission
paid to a related party
|
-
|
-
|
-
|
(414,509
|
)
|
||||||||
|
|||||||||||||
Net
loss
|
$
|
(567,770
|
)
|
$
|
(598,521
|
)
|
$
|
(1,884,986
|
)
|
$
|
(2,544,672
|
)
|
|
|
|||||||||||||
|
|||||||||||||
Other
comprehensive loss
|
|||||||||||||
Translation
adjustment
|
(3,834
|
)
|
(7,653
|
)
|
(40,075
|
)
|
(34,234
|
)
|
|||||
Comprehensive
loss
|
$
|
(571,604
|
)
|
$
|
(606,174
|
)
|
$
|
(1,925,061
|
)
|
$
|
(2,578,906
|
)
|
|
|
|||||||||||||
Net
(loss) from continuing operations per
common
share - basic and diluted
|
$
|
(0.006
|
)
|
$
|
(0.008
|
)
|
$
|
(0.022
|
)
|
$
|
(0.029
|
)
|
|
Net
loss on discontinued operations per
common
share - basic and diluted
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
(0.006
|
)
|
||||
Weighted
average number of common
shares
outstanding-basic and diluted
|
93,551,551
|
76,122,358
|
87,788,767
|
74,033,591
|
SEE
ACCOMPANYING NOTES
|
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(UNAUDITED)
|
Item
|
Nine
Months Ended September 30,
|
||||||
2008
|
2007
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
loss
|
$
|
(1,884,986
|
)
|
$
|
(2,544,672
|
)
|
|
Adjustments
to reconcile net loss to net cash used in
operating
activities:
|
|||||||
Depreciation
and amortization
|
241,230
|
212,001
|
|||||
Amortization
of detachable warrants, options and stocks as
compensation
|
641,045
|
966,950
|
|||||
Provision
for doubtful debt
|
42,367
|
10,879
|
|||||
(Gain)/Loss
on disposal of fixed assets
|
-
|
2,033
|
|||||
Minority
interest in a subsidiary
|
(31,956
|
)
|
8,778
|
||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable
|
(319,823
|
)
|
476,984
|
||||
Inventories
|
173,048
|
(154,927
|
)
|
||||
Prepaid
expenses
|
(5,188
|
)
|
(8,947
|
)
|
|||
Other
current assets
|
(65,863
|
)
|
(8,833
|
)
|
|||
Accounts
payable
|
480,765
|
656,468
|
|||||
Advances
from customers
|
116,891
|
34,891
|
|||||
Due
to related parties-trade
|
107,048
|
70,000
|
|||||
Net
cash provided by (used in) operating activities
|
(505,422
|
)
|
(278,395
|
)
|
|||
Cash
flows from investing activities:
|
|||||||
Purchase
of property and equipment
|
(87,677
|
)
|
(203,768
|
)
|
|||
Net
cash used in investing activities
|
(87,677
|
)
|
(203,768
|
)
|
|||
Cash
flows from financing activities:
|
|||||||
Proceeds
from issuance of common stock
|
650,000
|
-
|
|||||
Proceeds
from related parties
|
428,763
|
436,119
|
|||||
Repayment
to related parties
|
(511,115
|
)
|
(417,932
|
)
|
|||
Repayment
of long-term borrowings
|
(5,606
|
)
|
(4,627
|
)
|
|||
Net
cash provided by financing activities
|
562,042
|
13,560
|
|||||
Effect
of exchange rate changes on cash and cash
equivalents
|
13,145
|
20,252
|
|||||
Cash
and cash equivalents:
|
|||||||
Net
increase (decrease)
|
(17,912
|
)
|
(448,351
|
)
|
|||
Balance
at beginning of period
|
61,073
|
498,103
|
|||||
Balance
at end of period
|
$
|
43,161
|
$
|
49,752
|
|||
|
|||||||
Supplemental
Disclosures of Cash flow Information:
|
|||||||
Cash
paid for interest
|
$
|
1,433
|
$
|
302
|
|||
Cash
paid for taxes
|
$
|
-
|
$
|
-
|
|||
|
|||||||
Non-cash
investing and financing activities:
|
|||||||
Issuance
of detachable warrants in conjunction with loans
|
-
|
75,914
|
|||||
Issuance
of detachable warrants as compensation to
consultants
|
-
|
44,414
|
|||||
Issuance
of common stock for conversion of long-term
convertible
notes payable and interest
|
308,480
|
293,209
|
|||||
Issuance
of stock as compensation to consultants
|
19,600
|
126,000
|
|||||
Issuance
of stock for cashless exercise of warrants
|
-
|
1,707
|
|||||
Conversion
of accrued interests into principal
|
112,917
|
-
|
SEE
ACCOMPANYING NOTES
|
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
|
CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(DEFICIENCY)
|
(UNAUDITED)
|
Item
|
Common
Stock
|
Additional
Paid-in
|
Stock-based
Compensation
|
Accumulated
|
Other
Comprehensive
|
Total
Stockholders’
|
||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Reserve
|
Deficits
|
Income
|
Deficiency
|
|||||||||||||||
Balance,
December 31, 2007
|
81,519,676
|
81,520
|
9,217,876
|
(307,053
|
)
|
(11,074,522
|
)
|
(2,592
|
)
|
(2,084,771
|
)
|
|||||||||||
Issuance
of 140,000 shares of common stock to an Investor Relations consultant
on
February 27, 2008
|
140,000
|
140
|
19,460
|
-
|
-
|
-
|
19,600
|
|||||||||||||||
Issuance
of 5,000,000 shares of common stock to an investor
for
the consideration of $650,000 on March 14, 2008
|
5,000,000
|
5,000
|
645,000
|
-
|
-
|
-
|
650,000
|
|||||||||||||||
Issuance
of common stock for conversion of principal and
interest
of 6% Notes during nine months ended September 30,
2008
|
8,672,030
|
8,672
|
299,808
|
-
|
-
|
-
|
308,480
|
|||||||||||||||
Amortizaton
of fair value of warrants issued to a financing consultant during
nine
months ended September 30, 2008
|
-
|
-
|
-
|
57,886
|
-
|
-
|
57,886
|
|||||||||||||||
Amortization
of fari value of employee stock options granted
in
2006
|
-
|
-
|
-
|
65,548
|
-
|
-
|
65,548
|
|||||||||||||||
Net
loss for the nine months ended September 30, 2008
|
-
|
-
|
-
|
-
|
(1,884,986
|
)
|
-
|
(1,884,986
|
)
|
|||||||||||||
Other
comprehensive income for the nine months ended
September
30, 2008
|
-
|
-
|
-
|
-
|
-
|
(40,075
|
)
|
(40,075
|
)
|
|||||||||||||
Balance,
September 30, 2008
|
95,331,706
|
95,332
|
10,182,144
|
(183,619
|
)
|
(12,959,508
|
)
|
(42,667
|
)
|
(2,908,318
|
)
|
|||||||||||
SEE
ACCOMPANYING NOTES
|
Buildings
|
20-35
years
|
Machinery
and equipment
|
4-12
years
|
Automobiles
|
8
years
|
Office
equipments
|
5
years
|
Computer
software
|
3
years
|
Item
|
September
30, 2008
|
December
31, 2007
|
|||||
Accounts
receivables - gross
|
$
|
1,087,119
|
$
|
747,438
|
|||
Allowance
for doubtful accounts
|
(339,365
|
)
|
(277,140
|
)
|
|||
Accounts
receivables - net
|
$
|
747,754
|
$
|
470,298
|
Item
|
|
September
30, 2008
|
|
December
31, 2007
|
|||
Raw
materials
|
$
|
523,991
|
$
|
686,290
|
|||
Finished
goods
|
121,290
|
132,039
|
|||||
Total
|
$
|
645,281
|
$
|
818,329
|
Item
|
September
30, 2008
|
|
December
31, 2007
|
||||
Property
plant and equipment:
|
|||||||
Buildings
|
$
|
1,244,940
|
$
|
1,162,060
|
|||
Machinery
and equipment
|
707,367
|
660,273
|
|||||
Automobiles
|
81,586
|
76,154
|
|||||
Office
equipment
|
109,025
|
93,231
|
|||||
Computer
software
|
10,582
|
9,877
|
|||||
Property
plant and equipment - total
|
$
|
2,153,500
|
$
|
2,001,595
|
|||
Less:
Accumulated depreciation
|
(562,056
|
)
|
(433,690
|
)
|
|||
Property
plant and equipment - net
|
$
|
1,591,444
|
$
|
1,567,905
|
|
|||||||||||||
Amortization
Year
|
Gross
carrying value |
Accumulated
amount
of
amortization
|
Net
Value at
September
30,
2008
|
Net
value
at
December 31,
2007
|
|||||||||
8.5
|
$
|
480,411
|
$
|
214,493
|
$
|
265,918
|
$
|
296,245
|
Future
expected amortization
|
Amount
|
|||
2008
|
$
|
14,130
|
||
2009
|
56,519
|
|||
2010
|
56,519
|
|||
2011
|
56,519
|
|||
Thereafter
|
$
|
82,231
|
Item
|
September
30, 2008
|
|
December
31, 2007
|
||||
Consulting
and professional payables
|
$
|
369,010
|
$
|
436,381
|
|||
Payables
to material suppliers
|
826,313
|
425,306
|
|||||
Interest
payable
|
180,252
|
192,275
|
|||||
Salary
payable
|
295,038
|
212,219
|
|||||
Insurance
payable
|
104,911
|
95,247
|
|||||
Office
rental payable
|
86,735
|
80,960
|
|||||
Credit
card balance
|
80,350
|
84,042
|
|||||
Others
|
109,999
|
109,060
|
|||||
Total
|
$
|
2,052,608
|
$
|
1,635,490
|
Item
|
Nature
|
Notes
|
September
30, 2008
|
December
31, 2007
|
|||||||||
Mr.
Wei Li ("Mr. Li")
|
Non-trade
|
(1)
|
|
$
|
510,774
|
$
|
377,218
|
||||||
Discount
of loans due to Mr. Li with
|
Non-trade
|
-
|
(88,195
|
)
|
|||||||||
detachable
warrants
|
|||||||||||||
Kangtai
International Logistics (Beijing) Co., Ltd.
|
|||||||||||||
("Kangtai")
|
Non-trade
|
(2)
|
|
(57,277
|
)
|
205,631
|
|||||||
Ms.
Yvonne Wang ("Ms. Wang")
|
Non-trade
|
(3)
|
|
104,000
|
57,000
|
||||||||
Subtotal
|
$
|
557,497
|
$
|
551,654
|
|||||||||
Kiwa-CAU
R&D Center
|
Trade
|
(4)
|
|
256,662
|
164,280
|
||||||||
Tianjin
Challenge Feed Co., Ltd.
|
|||||||||||||
("Challenge
Feed")
|
Trade
|
(5)
|
|
14,666
|
13,690
|
||||||||
Subtotal
|
$
|
271,328
|
$
|
177,970
|
|||||||||
Total
|
$
|
828,824
|
$
|
729,624
|
Item
|
September
30, 2008
|
December
31, 2007
|
|||||
Unsecured
loan payable to Zoucheng Municipal Government, non-interest bearing,
becoming due within three years from Kiwa Shandong’s first profitable year
on a formula basis, interest has not been imputed due to the
undeterminable repayment date
|
$
|
1,319,977
|
$
|
1,232,100
|
|||
Unsecured
loan payable to Zoucheng Science & Technology Bureau, non-interest
bearing, it is due in Kiwa Shandong’s first profitable year, interest has
not been imputed due to the undeterminable repayment date
|
366,660
|
342,250
|
|||||
Total
|
$
|
1,686,637
|
$
|
1,574,350
|
Item
|
|
Bio-fertilizer
|
|
Livestock
Feed
|
|
Corporate
(1)
|
|
Total
|
|||||
Three
months ended September 30, 2008
|
|
||||||||||||
Net
sales
|
$
|
36,413
|
$
|
2,290,902
|
$
|
-
|
$
|
2,327,315
|
|||||
Gross
profit
|
5,988
|
49,555
|
-
|
55,543
|
|||||||||
Operating
expenses
|
122,140
|
79,463
|
284,830
|
486,433
|
|||||||||
Operating
profit (loss)
|
(116,152
|
)
|
(29,908
|
)
|
(284,830
|
)
|
(430,890
|
)
|
|||||
Interest
income (expense)
|
(55
|
)
|
(29
|
)
|
(142,784
|
)
|
(142,868
|
)
|
|||||
Minority
interest in subsidiary
|
-
|
5,988
|
-
|
5,988
|
|||||||||
Net
income (loss)
|
$
|
(116,207
|
)
|
$
|
(23,949
|
)
|
$
|
(427,614
|
)
|
$
|
(567,770
|
)
|
|
Total
assets as of September 30, 2008
|
$
|
2,151,965
|
$
|
1,184,187
|
$
|
375,395
|
$
|
3,711,547
|
|||||
Three
months ended September 30, 2007
|
|||||||||||||
Net
sales
|
$
|
106,538
|
$
|
2,851,434
|
$
|
-
|
$
|
2,957,972
|
|||||
Gross
profit
|
63,552
|
175,708
|
-
|
239,260
|
|||||||||
Operating
expenses
|
104,725
|
97,221
|
448,393
|
650,339
|
|||||||||
Operating
profit (loss)
|
(41,173
|
)
|
78,487
|
(448,393
|
)
|
(411,079
|
)
|
||||||
Interest
income (expense)
|
(8,886
|
)
|
7
|
(162,864
|
)
|
(171,743
|
)
|
||||||
Minority
interest in subsidiary
|
-
|
(15,699
|
)
|
-
|
(15,699
|
)
|
|||||||
(Loss)
from discontinued operations
|
-
|
-
|
-
|
-
|
|||||||||
Net
income (loss)
|
$
|
(50,059
|
)
|
$
|
62,795
|
$
|
(611,257
|
)
|
$
|
(598,521
|
)
|
||
Total
assets as of September 30, 2007
|
$
|
2,277,332
|
$
|
905,593
|
$
|
375,607
|
$
|
3,558,532
|
Fiscal
year
|
Amount
|
|||
2008
|
$
|
57,900
|
||
2009
|
56,700
|
|||
Total
|
$
|
164,800
|
|
|
Three
months ended September 30,
|
|
Change
|
|
||||||||
Item
|
|
2008
|
|
2007
|
|
Amount
|
|
Percentage
|
|||||
Bio-fertilizer:
|
|||||||||||||
Net
sales
|
$
|
36,413
|
$
|
106,538
|
$
|
(70,125
|
)
|
-65.8
|
%
|
||||
Quantity
(Tons)
|
32
|
91
|
(59
|
)
|
-64.9
|
%
|
|||||||
Average
price
|
$
|
1,138
|
$
|
1,168
|
$
|
(30
|
)
|
-2.6
|
%
|
||||
Bio-enhanced
feed:
|
|||||||||||||
Net
sales
|
$
|
2,290,902
|
$
|
2,851,434
|
$
|
(560,532
|
)
|
-19.7
|
%
|
||||
Quantity
(Tons)
|
5,444
|
7,550
|
(2,106
|
)
|
-27.9
|
%
|
|||||||
Average
price
|
$
|
421
|
$
|
378
|
$
|
43
|
11.4
|
%
|
|||||
Total
net sales
|
$
|
2,327,315
|
$
|
2,957,972
|
$
|
(630,657
|
)
|
-21.3
|
%
|
Bio-fertilizer
|
Changes
|
Bio-enhanced
feed
|
Changes
|
||||||||||||||||||||||
2008
Q3
|
2007
Q3
|
Amount
|
Percentage
|
2008
Q3
|
2007
Q3
|
Amount
|
Percentage
|
||||||||||||||||||
Net
Sales
|
$
|
36,413
|
$
|
106,538
|
$
|
(70,125
|
)
|
-65.8
|
%
|
$
|
2,290,902
|
$
|
2,851,434
|
$
|
(560,532
|
)
|
-19.7
|
%
|
|||||||
Cost
of Sales
|
30,425
|
42,986
|
(12,561
|
)
|
-29.2
|
%
|
2,241,347
|
2,675,725
|
(434,378
|
)
|
-16.2
|
%
|
|||||||||||||
Gross
Profit
|
$
|
5,988
|
$
|
63,552
|
$
|
(57,564
|
)
|
-90.6
|
%
|
$
|
49,555
|
$
|
175,709
|
$
|
(126,154
|
)
|
-71.8
|
%
|
|||||||
Gross
Profit Margin
|
16.4
|
%
|
59.7
|
%
|
2.2
|
%
|
6.2
|
%
|
Nine
months ended September 30,
|
|
Change
|
|
||||||||||
|
|
2008
|
|
2007
|
|
Amount
|
|
Percentage
|
|
||||
$
|
219,933
|
$
|
135,712
|
$
|
84,221
|
62.1
|
%
|
||||||
648
|
133
|
515
|
387.2
|
%
|
|||||||||
$
|
339
|
$
|
1,019
|
$
|
(680
|
)
|
-66.7
|
%
|
|||||
$
|
7,319,150
|
$
|
6,079,000
|
$
|
1,240,150
|
20.4
|
%
|
||||||
17,001
|
20,561
|
(3,560
|
)
|
-17.3
|
%
|
||||||||
$
|
431
|
$
|
296
|
$
|
135
|
45.8
|
%
|
||||||
$
|
7,539,083
|
$
|
6,214,712
|
$
|
1,324,371
|
21.3
|
%
|
Bio-fertilizer
|
|
Changes
|
|
Bio-enhanced
feed
|
|
Changes
|
|||||||||||||||||||
2008
Q1-Q3
|
|
2007
Q1-Q3
|
|
Amount
|
|
Percentage
|
|
2008
Q1-Q3
|
|
2007
Q1-Q3
|
|
Amount
|
|
Percentage
|
|||||||||||
Net
Sales
|
$
|
219,933
|
$
|
135,712
|
$
|
84,221
|
62.1
|
%
|
$
|
7,319,150
|
$
|
6,079,000
|
$
|
1,240,150
|
20.4
|
%
|
|||||||||
Cost
of Sales
|
160,254
|
66,038
|
94,216
|
142.7
|
%
|
7,193,380
|
5,697,349
|
1,496,031
|
26.3
|
%
|
|||||||||||||||
Gross
Profit
|
$
|
59,679
|
$
|
69,674
|
$
|
(9,995
|
)
|
-14.3
|
%
|
$
|
125,770
|
$
|
381,651
|
$
|
(255,881
|
)
|
-67.0
|
%
|
|||||||
Gross
Profit Margin
|
27.1
|
%
|
51.3
|
%
|
1.7
|
%
|
6.3
|
%
|
Exhibit
No.
|
Description
|
Incorporated
by Reference in Document
|
Exhibit
No. in Incorporated Document
|
|||
3.1
|
Certificate
of Incorporation, effective as of July 21, 2004.
|
Form
8-K filed on July 23, 2004
|
3.1
|
|||
3.2
|
Bylaws,
effective as of July 22, 2004.
|
Form
8-K Filed on July 23, 2004
|
3.2
|
|||
3.3
|
Certificate
of Amendment to Certificate of Incorporation, effective as of September
27, 2006.
|
Form
10-QSB filed on November 15, 2006
|
3.3
|
|||
10.1
|
Consulting
Agreement between the Company and Robert Schechter dated January
10,
2008
|
Form
10-Q filed on August 11, 2008
|
||||
10.2
|
Contract
for Joint Venture between the Company and Hebei Huaxing Pharmaceuticals
Co., Ltd. dated May 22, 2008
|
Form
8-K filed on May 27, 2008
|
10.1
|
|||
10.3
|
Term
Sheet for Redemption Convertible Notes dated September 25, 2008 between
the Company and AJW Offshore Ltd., AJW Qualified Partners LLC, AJW
Partners LLC, and New Millennium Capital Partners II LLC
|
Filed
herewith.
|
||||
10.4
|
Term
Sheet for Redemption Convertible Notes dated September 25, 2008 between
the Company and FirsTrust Group, Inc. dated October 7,
2008
|
Filed
herewith.
|
||||
21
|
List
of Subsidiaries
|
Form
10-KSB filed on April 2, 2007
|
21
|
|||
31.1
|
Certification
of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)
of the
Securities Exchange Act of 1934
|
Filed
herewith.
|
||||
31.2
|
Certification
of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)
of the
Securities Exchange Act of 1934
|
Filed
herewith.
|
||||
32.1
|
Certification
of Principal Executive Officer, pursuant to 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Filed
herewith.
|
||||
32.2
|
Certification
of Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
Filed
herewith.
|
/s/ Wei Li | November 12, 2008 Chief Executive Officer and Chairman of the Board of Directors | |
Wei Li |
(Principal
Executive Officer)
|
|
/s/ Lianjun Luo | November 12, 2008 Chief Financial Officer and Director | |
Lianjun Luo |
(Principal
Financial Officer and Principal Accounting Officer)
|
|